Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis

SpringerPlus

Table 7 Total discounted costs and QALYs for the treatment strategies

Treatment strategy	Cost-effectiveness analysis results without considering renal impact			Cost-effectiveness analysis results considering renal impact
Treatment strategy	Cost ($)	QALYs	ICER with respect to next best option	Cost ($)	QALYs	ICER with respect to next best option
Without sequencing
BSC	45,234	12.40	–	46,171	12.40	–
LAM	47,838	12.99	ED	48,679	12.99	ED
LDT	49,620	13.60	4066	50,257	13.60	3398
ADV	47,963	13.20	3435	52,423	13.20	D
ETV	50,640	13.71	D	51,248	13.71	D
TDF	64,413	13.27	D	65,291	13.27	D
LDT + ADV	51,829	13.66	D	52,446	13.66	D
LDT + TDF	59,267	12.78	D	60,114	12.78	D
With sequencing
LAM → ADV	48,878	13.18	D	54,976	13.18	D
ADV → LAM	48,231	13.17	D	54,560	13.17	D
LDT → ADV	50,275	13.72	5774	50,868	13.72	5385
ETV → ADV	50,819	13.74	27,205	51,422	13.74	27,741

ADV adefovir dipivoxil, BSC best supportive care, D dominated, ED extended dominance, ETV entecavir, ICER incremental cost-effectiveness ratio, LAM lamivudine, LDT telbivudine, QALY quality-adjusted life-year, TDF tenofovir